API
< Back to situation

[REVISION HISTORY]

Windward Bio US IPO process

1 recorded revision of this situation.

What changed

2026-11-13 19:43 UTC → 2026-11-17 10:06 UTC · added removed

Basel-based biotechnology company Windward Bio AG initiated its United States initial public offering (IPO) process by filing to raise up to $365 million. The company intends to use the funds to accelerate the development of long-acting antibody treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory skin diseases. Its lead candidate, WIN378, is designed to block thymic stromal lymphopoietin (TSLP) to reduce injection frequency for patients. Following the filing, Windward Bio completed its Nasdaq debut by pricing the IPO at $17 per share. The company raised a total gross proceeds of $225 approximately $251.2 million, consisting which included the full exercise of underwriters’ options. This total consists of $175 million from public investors and a $50 million through a concurrent private placement with Sanofi. Sanofi Foreign Participations B.V. These funds are earmarked for clinical trials of next-generation biologic drugs. The company continues to focus on WIN378, which aims drugs, specifically for lead candidates WIN378 and WIN027. WIN378 is currently being evaluated in Phase 2/3 asthma and Phase 2 COPD studies, aiming to provide dosing every six months. Following its market debut, the company reached a market capitalization of approximately $1.69 billion. Windward Bio utilizes a model of licensing clinical-stage assets from various Chinese biotechnology firms. firms, including programs from Sichuan Kelun-Biotech Biopharmaceutical, Harbour BioMed, and Qyuns Therapeutics.

Versions

  1. 2026-11-17 10:06 UTC Windward Bio US IPO process
  2. 2026-11-13 19:43 UTC Windward Bio US IPO process

Select a version to see what changed compared to the one before it.